Dimethyl fumarate for multiple sclerosis
Z Xu, F Zhang, FL Sun, KF Gu… - Cochrane Database of …, 2015 - cochranelibrary.com
Z Xu, F Zhang, FL Sun, KF Gu, S Dong, D He
Cochrane Database of Systematic Reviews, 2015•cochranelibrary.comBackground Multiple sclerosis (MS) often leads to severe neurological disability and a
serious decline in quality of life. The ideal target of disease‐modifying therapy for MS is to
prevent disability worsening and improve quality of life. Dimethyl fumarate is considered to
have an immunomodulatory activity and neuroprotective effect. It has been approved by the
US Food and Drug Administration (FDA) and the European Medicines Agency as a first‐line
therapy for adult patients with relapsing‐remitting MS (RMSS). Objectives To assess the …
serious decline in quality of life. The ideal target of disease‐modifying therapy for MS is to
prevent disability worsening and improve quality of life. Dimethyl fumarate is considered to
have an immunomodulatory activity and neuroprotective effect. It has been approved by the
US Food and Drug Administration (FDA) and the European Medicines Agency as a first‐line
therapy for adult patients with relapsing‐remitting MS (RMSS). Objectives To assess the …
Background
Multiple sclerosis (MS) often leads to severe neurological disability and a serious decline in quality of life. The ideal target of disease‐modifying therapy for MS is to prevent disability worsening and improve quality of life. Dimethyl fumarate is considered to have an immunomodulatory activity and neuroprotective effect. It has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency as a first‐line therapy for adult patients with relapsing‐remitting MS (RMSS).
Objectives
To assess the benefit and safety of dimethyl fumarate as monotherapy or combination therapy versus placebo or other approved disease‐modifying drugs (interferon beta, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab) for patients with MS.
cochranelibrary.com